<DOC>
	<DOCNO>NCT01751776</DOCNO>
	<brief_summary>To evaluate safety tolerability multiple dos BI 655064 administer subcutaneously healthy volunteer ( HVs ) rheumatoid arthritis ( RA ) patient . To explore pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameters multiple dos BI 655064 healthy volunteer ( HVs ) rheumatoid arthritis ( RA ) patient . To assess clinical effect BI 655064 RA patient prior inadequate response methotrexate ( MTX ) 12 week treatment</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Clinical Effects Multiple Rising Subcutaneous Doses BI 655064 Healthy Volunteers Rheumatoid Arthritis Patients With Prior Inadequate Response Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : Part 1 ( phase Ib ) ( HVs ) : 1 . Healthy male female accord investigator assessment , base follow criterion : complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 2 . Age &gt; = 18 &lt; = 60 year 3 . Body Mass Index &gt; = 18.5 &lt; = 29.9 kg/m2 4 . Signed date write informed consent prior admission study accordance GCP local legislation 5 . Female subject meet follow criterion least 30 day first study drug administration 30 day trial completion : use adequate contraception , e.g . follow method plus condom : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) sexually abstinent vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) surgically sterilise ( include hysterectomy ) postmenopausal define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level follicle stimulate hormone ( FSH ) 40 U/L estradiol 30 ng/L confirmatory ) Part 2 ( phase IIa ) ( RA Patients ) : 1 . Age &gt; = 18 &lt; = 70 year 2 . Patients classify RA accord 1987 ACR Classification Criteria 3 . Inadequate clinical response methotrexate monotherapy define moderate/high active disease oral s.c. MTX treatment give continuously least 3 month last 6 week screen stable weekly dose &gt; =15mg . For patient tolerate minimum weekly dose least 15 mg due side effect , stable weekly dose low 7.5 mg also permit . 4 . DAS28 4vCRP &gt; = 3.5 &gt; = 6 tender &gt; = 6 swollen joint 68/66 joint count screening confirm &gt; = 6 tender &gt; = 6 swollen joint 68/66 joint count randomisation visit ( Visit 2 ) 5 . Serum CRP level &gt; = 0.8 mg/dL ESR &gt; = 28 mm/1h screen 6 . AntiCCP2 Rheumatoid Factor positivity per limit use assay screen 7 . Female patient meet follow criterion least 30 day first study drug administration least 6 month last dose MTX take current trial : use adequate contraception , e.g . follow method plus condom : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) sexually abstinent vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) surgically sterilise ( include hysterectomy ) postmenopausal define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level follicle stimulate hormone ( FSH ) 40 U/L estradiol 30 ng/L confirmatory ) OR Male patient : document sterile consistently correctly use condom female partner ( childbearing potential ) agree use follow adequate contraception method : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) date screen least 6 month last dose MTX take current trial don¿t donate sperm sample procreation purpose , date screening least 6 month last dose MTX take current trial . 8 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : Part 1 ( phase Ib HVs ) : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator 2 . Any laboratory value outside reference range investigator considers clinical relevance 3 . Any evidence concomitant disease judge clinically relevant investigator 4 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 5 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder 6 . History relevant orthostatic hypotension , faint spell , blackouts 7 . History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) 9 . Within 10 day prior administration trial medication , use drug might reasonably influence result trial 12 . Alcohol abuse ( consumption 140 g/week female 210 g/week male ) 13 . Drug abuse positive drug screen 17 . Chronic relevant acute infection , include limited HIV , Hepatitis B C tuberculosis ( include history clinical TB and/or positive QuantiFERON TBGold test ) 18 . Subject assessed investigator unsuitable inclusion e.g . consider able understand comply study requirement condition would allow safe participation study 19 . Positive pregnancy test , pregnancy plan become pregnant within 30 day study completion 20 . Lactation Further exclusion criterion applicable part 1 give CTP . Part 2 ( phase IIa RA patient ) : Part 1 ( phase Ib ) exclusion criterion 7 , 9 , 12 , 13 1720 plus : 1 . Current previous use two antiTNF biologic drug use biologic agent target approve mechanism ( biologic drug mechanism action direct antiTNF blockade , ( e.g . CTLA4 , antiIL6 , anti CD20 ) new oral compound target approve mechanism ( e.g . JAK inhibitor ) treat RA . 2 . Current previous participation clinical trial test investigational drug RA within 3 month prior screen within 5 halflives investigational drug , whichever long , except previous participation trial test NSAIDs , corticosteroid , analgesic patient document receive placebo previous RA trial . 3 . DAS28 &lt; 3.2 least 2 occasion last 6 month screen 4 . RA patient severe disability ( functional class IV ) confirm severe systemic manifestation e.g . know amyloidosis , Felty´s syndrome , lymphoproliferative disorder , rheumatoid vasculitis 5 . Treatment standard DMARD except MTX ( include limit sulfasalazine , leflunomide , hydroxychloroquine , Dpenicillamine 6 . Impaired hepatic function , define serum AST/ALT , bilirubin alkaline phosphatase level &gt; 2 x ULN 7 . Impaired renal function define calculated creatinine clearance &lt; 50ml/min 8 . Preexisting blood dyscrasia e.g . bone marrow hypoplasia , significant anaemia , leucopenia thrombocytopenia 9 . Hypersensitivity MTX excipients 10 . Previous intolerance MTX main cause stop treatment ( instead lack efficacy ) 11 . Any active suspected malignancy history document malignancy within last 5 year screen , except appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>